GLP-1R Agonists Modulate Enteric Immune Responses Through the Intestinal Intraepithelial Lymphocyte GLP-1R
The DOI matches its Crossref record; 52 of the 56 references it cites were found in a registry or an index.
Abstract
Obesity and diabetes are characterized by increased inflammation reflecting disordered control of innate immunity. We reveal a local intestinal intraepithelial lymphocyte (IEL)-GLP-1 receptor (GLP-1R) signaling network that controls mucosal immune responses. Glp1r expression was enriched in intestinal IEL preparations and copurified with markers of Tαβ and Tγδ IELs, the two main subsets of intestinal IELs. Exendin-4 increased cAMP accumulation in purified IELs and reduced the production of cytokines from activated IELs but not from splenocytes ex vivo. These actions were mimicked by forskolin, absent in IELs from Glp1r−/− mice, and attenuated by the GLP-1R agonist exendin (9-39) consistent with a GLP-1R–dependent mechanism of action. Furthermore, Glp1r−/− mice exhibited dysregulated intestinal gene expression, an abnormal representation of microbial species in feces, and enhanced sensitivity to intestinal injury following administration of dextran sodium sulfate. Bone marrow transplantation using wild-type C57BL/6 donors normalized expression of multiple genes regulating immune function and epithelial integrity in Glp1r−/− recipient mice, whereas acute exendin-4 administration robustly induced the expression of genes encoding cytokines and chemokines in normal and injured intestine. Taken together, these findings define a local enteroendocrine-IEL axis linking energy availability, host microbial responses, and mucosal integrity to the control of innate immunity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the inflammatory environment, the M1 to M2 shift promoted by GLP-1 is crucial for reducing the expression of inflammatory factors such as IL-6, TNF-α, and iNOS.8,15,328”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [328]
In the citing paper
“Thymus, bone marrow, spleen, mesenteric lymph nodes, brachial/axillary lymph nodes, inguinal lymph nodes, and PBMCs express low levels of Glp1r (29, 33, 34).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [33]
In the citing paper
“In the small intestine, intraepithelial lymphocytes (IELs) express high levels of Glp1r, triggering cAMP response upon activation by exendin-4 (33).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [33]
In the citing paper
“Glp1r–/– mice exhibited exacerbated intestinal inflammation in a dextran sulfate sodium–induced model of colitis (33).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [33]
In the citing paper
“Notably, GLP-1R expression in gut IELs is significantly lower in the colon than in the small intestine (33), suggesting that other cell types, such as enteric neurons (82), may contribute to the antiinflammatory actions of GLP-1 medicines in the colon.”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [33]
Citations
Cites
Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
Chomczynski, P., & Sacchi, N. (1987) · Analytical Biochemistry · doi:10.1016/0003-2697(87)90021-2 · Cited by 46,426 · cited 11×
“These actions were mimicked by forskolin, absent in IELs from Glp1r mice, and attenuated by the GLP-1R agonist exendin (9-39) consistent with a GLP-1R–dependent mechanism of action.”
BackgroundMethodInfluentialInflammation and metabolic disorders
Hotamisligil, G. S. (2006) · Nature · doi:10.1038/nature05485 · Cited by 9,199 · cited 11×
“These actions were mimicked by forskolin, absent in IELs from Glp1r mice, and attenuated by the GLP-1R agonist exendin (9-39) consistent with a GLP-1R–dependent mechanism of action.”
BackgroundMethodInfluentialDrucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“GLP-1 controls gut motility and food intake and stimulates insulin while simultaneously inhibiting glucagon secretion (4,5).”
BackgroundSelf-citationCani, P. D., Possemiers, S., Van de Wiele, T., Guiot, Y., Everard, A., Rottier, O., Geurts, L., Naslain, D., Neyrinck, A., Lambert, D. M., et al. (2009) · Gut · doi:10.1136/gut.2008.165886 · Cited by 2,518 · cited 1×
“Indeed, modulation (both gain and loss) of GLP-2R signaling robustly modifies gut barrier function and the extent of inflammation in murine models of diabetes characterized by gut injury and endotoxemia (46).”
BackgroundIntegrative analysis of environmental sequences using MEGAN4
Huson, D. H., Mitra, S., Ruscheweyh, H.-J., Weber, N., & Schuster, S. C. (2011) · Genome Research · doi:10.1101/gr.120618.111 · Cited by 1,541 · cited 11×
“These actions were mimicked by forskolin, absent in IELs from Glp1r mice, and attenuated by the GLP-1R agonist exendin (9-39) consistent with a GLP-1R–dependent mechanism of action.”
BackgroundMethodInfluentialPharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500 · cited 9×
“Indeed, transient blockade of GLP-1 receptor (GLP-1R) signaling reduces insulin, increases glucagon, and impairs glucose tolerance in multiple species (4).”
BackgroundInfluentialSelf-citationEllingsgaard, H., Hauselmann, I., Schuler, B., Habib, A. M., Baggio, L. L., Meier, D. T., Eppler, E., Bouzakri, K., Wueest, S., Muller, Y. D., et al. (2011) · Nature Medicine · doi:10.1038/nm.2513 · Cited by 922 · cited 3×
“GLP-1-(7-36) amide: northern blot, cross-linking, and radioligand binding.”
BackgroundSelf-citationPyke, C., Heller, R. S., Kirk, R. K., Ørskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., & Knudsen, L. B. (2014) · Endocrinology · doi:10.1210/en.2013-1934 · Cited by 876 · cited 11×
“These actions were mimicked by forskolin, absent in IELs from Glp1r mice, and attenuated by the GLP-1R agonist exendin (9-39) consistent with a GLP-1R–dependent mechanism of action.”
BackgroundMethodInfluentialThe light and dark sides of intestinal intraepithelial lymphocytes
Cheroutre, H., Lambolez, F., & Mucida, D. (2011) · Nature Reviews Immunology · doi:10.1038/nri3007 · Cited by 693 · cited 11×
“These actions were mimicked by forskolin, absent in IELs from Glp1r mice, and attenuated by the GLP-1R agonist exendin (9-39) consistent with a GLP-1R–dependent mechanism of action.”
BackgroundMethodInfluentialGlucagon‐like peptide‐1 cells in the gastrointestinal tract and pancreas of rat, pig and man
EISSELE, R., GÖKE, R., WILLEMER, S., HARTHUS, H. ‐., VERMEER, H., ARNOLD, R., & GÖKE, B. (1992) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1992.tb01464.x · Cited by 654 · cited 1×
“Proglucagon-producing L cells are among the most intensively studied enteroendocrine cells predominantly localized to the distal small bowel and colon (3).”
Background
Cited by
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
“The localization of GLP-1R expression to intestinal IELS within the immune system (Yusta et al., 2015) does not link direct activation of the immune GLP-1R to reduction of vascular or cardiac inflammation.”
BackgroundInfluentialSelf-citationCOVID-19 and diabetes mellitus: from pathophysiology to clinical management
Lim, S., Bae, J. H., Kwon, H.-S., & Nauck, M. A. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00435-4 · Cited by 1,006
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
The Cardiovascular Biology of Glucagon-like Peptide-1
Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665
Self-citationGlucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
Ussher, J. R., & Drucker, D. J. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00849-3 · Cited by 577
Self-citationAnxiety, depression, and the microbiome: A role for gut peptides
Lach, G., Schellekens, H., Dinan, T. G., & Cryan, J. F. (2018) · Neurotherapeutics · doi:10.1007/s13311-017-0585-0 · Cited by 573
Rakipovski, G., Rolin, B., Nøhr, J., Klewe, I., Frederiksen, K. S., Augustin, R., Hecksher-Sørensen, J., Ingvorsen, C., Polex-Wolf, J., & Knudsen, L. B. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.09.004 · Cited by 509
“Another location for GLP-1R expression is intestinal intraepithelial lymphocytes (IELs) (42).”
BackgroundDiscovery, characterization, and clinical development of the glucagon-like peptides
Drucker, D. J., Habener, J. F., & Holst, J. J. (2017) · Journal of Clinical Investigation · doi:10.1172/jci97233 · Cited by 418
Self-citationThe anti-inflammatory and immunological properties of GLP-1 Receptor Agonists
Bendotti, G., Montefusco, L., Lunati, M. E., Usuelli, V., Pastore, I., Lazzaroni, E., Assi, E., Seelam, A. J., El Essawy, B., Jang, J., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106320 · Cited by 406
Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent
Mehdi, S. F., Pusapati, S., Anwar, M. S., Lohana, D., Kumar, P., Nandula, S. A., Nawaz, F. K., Tracey, K., Yang, H., LeRoith, D., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1148209 · Cited by 317
Wong, C. K., McLean, B. A., Baggio, L. L., Koehler, J. A., Hammoud, R., Rittig, N., Yabut, J. M., Seeley, R. J., Brown, T. J., & Drucker, D. J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2023.11.009 · Cited by 304
“8,11 Although some anti-inflammatory effects of GLP-1RAs have been attributed to GLP-1R-expressing T cells, 8,14,15 the T cell GLP-1R alone was insufficient to explain the anti-in-flammatory actions of GLP-1RAs on myeloid cells.”
BackgroundSelf-citationGLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
Ma, X., Liu, Z., Ilyas, I., Little, P. J., Kamato, D., Sahebka, A., Chen, Z., Luo, S., Zheng, X., Weng, J., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59965 · Cited by 299
“The development of diabetes and obesity is underpinned by chronic inflammation [143].”
BackgroundRevisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
McLean, B. A., Wong, C. K., Campbell, J. E., Hodson, D. J., Trapp, S., & Drucker, D. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa032 · Cited by 289
Self-citationWorthington, J. J., Reimann, F., & Gribble, F. M. (2018) · Mucosal Immunology · doi:10.1038/mi.2017.73 · Cited by 262
Enterochromaffin 5-HT cells – A major target for GLP-1 and gut microbial metabolites
Lund, M. L., Egerod, K. L., Engelstoft, M. S., Dmytriyeva, O., Theodorsson, E., Patel, B. A., & Schwartz, T. W. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.03.004 · Cited by 254
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Hammoud, R., & Drucker, D. J. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00783-3 · Cited by 244
Self-citationThe expanding incretin universe: from basic biology to clinical translation
Drucker, D. J., & Holst, J. J. (2023) · Diabetologia · doi:10.1007/s00125-023-05906-7 · Cited by 243
Self-citationEnteroendocrine L Cells Sense LPS after Gut Barrier Injury to Enhance GLP-1 Secretion
Lebrun, L. J., Lenaerts, K., Kiers, D., Pais de Barros, J.-P., Le Guern, N., Plesnik, J., Thomas, C., Bourgeois, T., Dejong, C. H. C., Kox, M., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.008 · Cited by 238
“Indeed, both Paneth cells (known to produce antimicrobial components) and intestinal intraepithelial lymphocytes have been reported to express a functional GLP-1R (Kedees et al., 2013; Yusta et al., 2015), and loss of the GLP-1R increases the severity of DSS-induced intestinal injury (Yusta et al., 2015).”
BackgroundInfluentialSelf-citationIntestinal Barrier and Permeability in Health, Obesity and NAFLD
Portincasa, P., Bonfrate, L., Khalil, M., Angelis, M. D., Calabrese, F. M., D’Amato, M., Wang, D. Q.-H., & Di Ciaula, A. (2021) · Biomedicines · doi:10.3390/biomedicines10010083 · Cited by 211
Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease
Yabut, J. M., & Drucker, D. J. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnac018 · Cited by 175
Self-citationGut intraepithelial T cells calibrate metabolism and accelerate cardiovascular disease
He, S., Kahles, F., Rattik, S., Nairz, M., McAlpine, C. S., Anzai, A., Selgrade, D., Fenn, A. M., Chan, C. T., Mindur, J. E., et al. (2019) · Nature · doi:10.1038/s41586-018-0849-9 · Cited by 167
Self-citationThe benefits of GLP-1 drugs beyond obesity
Drucker, D. J. (2024) · Science · doi:10.1126/science.adn4128 · Cited by 165
Self-citationCrosstalk between glucagon-like peptide 1 and gut microbiota in metabolic diseases
Zeng, Y., Wu, Y., Zhang, Q., & Xiao, X. (2024) · mBio · doi:10.1128/mbio.02032-23 · Cited by 150
Linking microbiota to human diseases: a systems biology perspective
Wu, H., Tremaroli, V., & Bäckhed, F. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.09.011 · Cited by 150
“The gut microbiota also affects the enteroendocrine system and has been shown to modulate gut hormones such as glucagon-like peptide 1 (GLP-1) [33,34], which decreases food intake and promotes insulin sensitivity [35] but also has important local effects in the gut including modulation of intraepithelial lymphocytes a…”
BackgroundEmerging concepts in intestinal immune control of obesity-related metabolic disease
Khan, S., Luck, H., Winer, S., & Winer, D. A. (2021) · Nature Communications · doi:10.1038/s41467-021-22727-7 · Cited by 149
Wong, C. K., Yusta, B., Koehler, J. A., Baggio, L. L., McLean, B. A., Matthews, D., Seeley, R. J., & Drucker, D. J. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.08.003 · Cited by 138
Self-citationInflammation meets metabolic disease: Gut feeling mediated by GLP-1
Zietek, T., & Rath, E. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00154 · Cited by 131
“Locally increased GLP-1 levels might exert paracrine functions on IEL (50) and afferent neurons, impacting mucosal immune responses and feeding patterns, respectively.”
BackgroundInfluentialMicrobial regulation of GLP-1 and L-cell biology
Greiner, T. U., & Bäckhed, F. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.05.012 · Cited by 131
“com immunomodulatory genes and antimicrobial peptides [58].”
Zhao, L., Li, Z., Vong, J. S. L., Chen, X., Lai, H.-M., Yan, L. Y. C., Huang, J., Sy, S. K. H., Tian, X., Huang, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18249-3 · Cited by 126
Madsen, M. S. A., Holm, J. B., Pallejà, A., Wismann, P., Fabricius, K., Rigbolt, K., Mikkelsen, M., Sommer, M., Jelsing, J., Nielsen, H. B., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-52103-x · Cited by 121
GLP-1 receptor agonist as a modulator of innate immunity
Chen, J., Mei, A., Wei, Y., Li, C., Qian, H., Min, X., Yang, H., Dong, L., Rao, X., & Zhong, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.997578 · Cited by 120
“Diabetes mellitus is characterized by increased inflammation, reflecting innate immune control disorders, and studies have shown a local intestinal intraepithelial lymphocyte (IEL)-GLP-1 receptor (GLP-1R) signaling network that controls the mucosal immune response (43).”
BackgroundGLP-1 and GLP-2 Orchestrate Intestine Integrity, Gut Microbiota, and Immune System Crosstalk
Abdalqadir, N., & Adeli, K. (2022) · Microorganisms · doi:10.3390/microorganisms10102061 · Cited by 119
“Studies have shown that GLP-1 treatment can ameliorate dextran sulfate (DSS)-induced colitis [3,109,127].”
BackgroundInfluentialBerberine Attenuates Intestinal Mucosal Barrier Dysfunction in Type 2 Diabetic Rats
Gong, J., Hu, M., Huang, Z., Fang, K., Wang, D., Chen, Q., Li, J., Yang, D., Zou, X., Xu, L., et al. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00042 · Cited by 115
“Intestinal immune molecules could also affect GLP-1 secretion from ileal L cells, and anti-TNF-α therapy could reverse high fat diet induced reduction of GLP-1 in diabetic mice (Everard et al., 2013; Anhe et al., 2015; Luck et al., 2015; Yusta et al., 2015).”
BackgroundIntestinal Sensing by Gut Microbiota: Targeting Gut Peptides
Covasa, M., Stephens, R. W., Toderean, R., & Cobuz, C. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00082 · Cited by 112
“For example, administration of Exendin-4, a GLP-1 receptor agonist significantly reduced inflammatory cytokines and macrophage infiltration (153, 154).”
BackgroundWorthington, J. J. (2015) · Biochemical Society Transactions · doi:10.1042/bst20150090 · Cited by 112
GLP-1 Induces Barrier Protective Expression in Brunnerʼs Glands and Regulates Colonic Inflammation
Bang-Berthelsen, C. H., Holm, T. L., Pyke, C., Simonsen, L., Søkilde, R., Pociot, F., Heller, R. S., Folkersen, L., Kvist, P. H., Jackerott, M., et al. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000847 · Cited by 111
Gut microbiota regulates gut homeostasis, mucosal immunity and influences immune-related diseases
Ding, G., Yang, X., Li, Y., Wang, Y., Du, Y., Wang, M., Ye, R., Wang, J., Zhang, Y., Chen, Y., et al. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05077-y · Cited by 127
“Information from the intestinal lumen (bacterial products) through GLP-1-IEL-GLP-1R axis may regulate innate immunity to control the host mucosal immune response [53].”
Mulvihill, E. E., Varin, E. M., Gladanac, B., Campbell, J. E., Ussher, J. R., Baggio, L. L., Yusta, B., Ayala, J., Burmeister, M. A., Matthews, D., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2016.10.007 · Cited by 102
Self-citationMulvihill, E. E., Varin, E. M., Ussher, J. R., Campbell, J. E., Bang, K. W. A., Abdullah, T., Baggio, L. L., & Drucker, D. J. (2016) · Diabetes · doi:10.2337/db15-1224 · Cited by 101
“Protein levels of MCP-1 (mouse) and transforming growth factor-b1 (TGF-b1) (human) were quantified in heart extracts using Cytometric Bead Array assays (BD Biosciences) (20).”
MethodSelf-citationAntiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits
Wong, C. K., & Drucker, D. J. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194751 · Cited by 112
“Thymus, bone marrow, spleen, mesenteric lymph nodes, brachial/axillary lymph nodes, inguinal lymph nodes, and PBMCs express low levels of Glp1r (29, 33, 34).”
InfluentialSelf-citationHelmstädter, J., Keppeler, K., Küster, L., Münzel, T., Daiber, A., & Steven, S. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15462 · Cited by 99
“The activation of the GLP-1 receptor on intestinal intraepithelial lymphocytes within the immune system has been related to local modulation of the intestinal inflammatory responses (Yusta et al., 2015).”
BackgroundLarraufie, P., Doré, J., Lapaque, N., & Blottière, H. M. (2017) · Cellular Microbiology · doi:10.1111/cmi.12648 · Cited by 99
Tsai, C.-Y., Lu, H.-C., Chou, Y.-H., Liu, P.-Y., Chen, H.-Y., Huang, M.-C., Lin, C.-H., & Tsai, C.-N. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.814770 · Cited by 92
“GLP-1 RA modulates enteric immune responses as well as gut microbiota in murine models (61).”
BackgroundDissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1
Paternoster, S., & Falasca, M. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00584 · Cited by 91
Mosenzon, O., Capehorn, M. S., De Remigis, A., Rasmussen, S., Weimers, P., & Rosenstock, J. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01585-7 · Cited by 91
“Some possible mechanisms for this action include GLP-1 receptor expression in the intestine, which would lead to an improved gut barrier function [39, 40], or reprogramming of macrophages [41].”
BackgroundRichards, P., Thornberry, N. A., & Pinto, S. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101175 · Cited by 92
McLean, B. A., Wong, C. K., Kaur, K. D., Seeley, R. J., & Drucker, D. J. (2021) · JCI Insight · doi:10.1172/jci.insight.153732 · Cited by 84
Self-citationIntestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in Western diet-fed mice
Finn, P. D., Rodriguez, D., Kohler, J., Jiang, Z., Wan, S., Blanco, E., King, A. J., Chen, T., Bell, N., Dragoli, D., et al. (2019) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00300.2018 · Cited by 81
Molecular and Pathophysiological Links between Metabolic Disorders and Inflammatory Bowel Diseases
Hyun, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179139 · Cited by 90
“Secretion of GLP-1 and GLP-2 also has been found to be impaired by chronic exposure to TNFα [52,53] and, inversely, it was reported that GLP-1 or GLP-1 receptor (GLP-1R) agonists reduce the levels of pro-inflammatory cytokines [54] and the activation of GLP-1R signaling modulates intestinal immune responses and mucosa…”
BackgroundPlasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans
Baggio, L. L., Varin, E. M., Koehler, J. A., Cao, X., Lokhnygina, Y. V., Stevens, S. R., Holman, R. R., & Drucker, D. J. (2020) · Nature Communications · doi:10.1038/s41467-020-17556-z · Cited by 88
Self-citationThe Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications
Drucker, D. J. (2018) · Diabetes · doi:10.2337/dbi18-0008 · Cited by 78
Self-citationA GLP‐1/GLP‐2 receptor dual agonist to treat NASH: Targeting the gut‐liver axis and microbiome
Kim, E. R., Park, J. S., Kim, J. H., Oh, J. Y., Oh, I. J., Choi, D. H., Lee, Y. S., Park, I. S., Kim, S., Lee, D. H., et al. (2022) · Hepatology · doi:10.1002/hep.32235 · Cited by 77
de Paiva, I. H. R., da Silva, R. S., Mendonça, I. P., de Souza, J. R. B., & Peixoto, C. A. (2024) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-024-10142-w · Cited by 75
“A similar GLP-1R knockout mice (GLP-1R KO) worsens the intes - tinal damage effect (Yusta et al. 2015 ).”
Actions of glucagon‐like peptide‐1 receptor ligands in the gut
Holst, J. J., Andersen, D. B., & Grunddal, K. V. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15611 · Cited by 73
Bifari, F., Manfrini, R., Dei Cas, M., Berra, C., Siano, M., Zuin, M., Paroni, R., & Folli, F. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.09.025 · Cited by 69
Glucagon and glucagon-like peptide-1 as novel anti-inflammatory and immunomodulatory compounds
Insuela, D. B. R., & Carvalho, V. F. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.07.015 · Cited by 72
Hunt, J. E., Holst, J. J., Jeppesen, P. B., & Kissow, H. (2021) · Biomedicines · doi:10.3390/biomedicines9040383 · Cited by 65
“Subsequently, Yusta et al. 2015 [36] aimed to evaluate the importance of GLP-1 signaling in a localized inflammatory setting with the use of the GLP-1r knockout (GLP-1r KO) mouse and a dextran sodium sulfate (DSS)-induced colitis model of UC.”
BackgroundMethodInfluentialEvolving Concepts and Translational Relevance of Enteroendocrine Cell Biology
Drucker, D. J. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3449 · Cited by 63
Self-citationNozu, T., Miyagishi, S., Kumei, S., Nozu, R., Takakusaki, K., & Okumura, T. (2018) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13808 · Cited by 62
Circadian Rhythms and the Gastrointestinal Tract: Relationship to Metabolism and Gut Hormones
Martchenko, A., Martchenko, S. E., Biancolin, A. D., & Brubaker, P. L. (2020) · Endocrinology · doi:10.1210/endocr/bqaa167 · Cited by 75
Khan, M. T., Zohair, M., Khan, A., Kashif, A. W., Mumtaz, S., & Muskan, F. (2025) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2025.112599 · Cited by 77
Obesity, diabetes, and inflammation: Pathophysiology and clinical implications
Donath, M. Y., & Drucker, D. J. (2025) · Immunity · doi:10.1016/j.immuni.2025.09.011 · Cited by 69
Self-citationLiddle, R. A. (2019) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2019.01.006 · Cited by 69
“may influence immune function through effects on intraepithelial lymphocytes and afferent neurons.(58) Thus, despite our historical focus on the actions of circulating glucagon-like peptides and their exploitation for therapeutic purposes, locally released GLP-1 and GLP-2 may exert important and previously unappreciat…”
BackgroundLiu, M., Guo, S., Li, X., Tian, Y., Yu, Y., Tang, L., Sun, Q., Zhang, T., Fan, M., Zhang, L., et al. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s484531 · Cited by 68
Swanson, G. R., Siskin, J., Gorenz, A., Shaikh, M. W., Raeisi, S., Fogg, L., Forsyth, C. B., & Keshavarzian, A. (2020) · Translational research · doi:10.1016/j.trsl.2020.04.004 · Cited by 65
“Butyrate or propionate, are also both potent inhibitors of histone deacetylase (HDAC), and an increase in HDAC1 and HDAC2 has been shown to prevent intestinal inflammation and colitis.(53,58) Furthermore, circadian regulation of intestinal microbiota may be mediated through HDAC.”
BackgroundInventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity
Knudsen, L. B. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00048 · Cited by 56
Zatorski, H., Sałaga, M., & Fichna, J. (2019) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-019-01698-z · Cited by 55
Andersen, D. B., Grunddal, K. V., Pedersen, J., Kuhre, R. E., Lund, M. L., Holst, J. J., & Ørskov, C. (2021) · Endocrinology · doi:10.1210/endocr/bqaa246 · Cited by 54
Holst, J. J., Albrechtsen, N. J. W., Rosenkilde, M. M., & Deacon, C. F. (2019) · Comprehensive Physiology · doi:10.1002/cphy.c180013 · Cited by 54
Pang, J., Feng, J. N., Ling, W., & Jin, T. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.06.003 · Cited by 52
GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms
Mullur, N., Morissette, A., Morrow, N. M., & Mulvihill, E. E. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0046 · Cited by 51
Role of Incretin Axis in Inflammatory Bowel Disease
Duan, L., Rao, X., Braunstein, Z., Toomey, A. C., & Zhong, J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01734 · Cited by 57
Dynamic Metabolic State of Tissue Resident CD8 T Cells
Konjar, Š., & Veldhoen, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01683 · Cited by 53
“Recent data indicates that the GLP-1R pathway in IELs can determine systemic metabolic capacity, whereby GLP-1 is released from enteroendocrine L-cells in gut epithelium (86).”
BackgroundInfluentialActivation of ectopic olfactory receptor 544 induces GLP-1 secretion and regulates gut inflammation
Wu, C., Jeong, M.-Y., Kim, J. Y., Lee, G., Kim, J., Cheong, Y. E., Kang, H., Cho, C. H., Kim, J., Park, M. K., et al. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1987782 · Cited by 54
“The anti-inflammatory effects of GLP-1 and GLP-1 analogues have been explored in different tissues, including the colon.(54,55) Furthermore, the gut microbiota contributes to obesity-induced chronic-low grade inflammation.”
BackgroundCherney, D. Z. I., Udell, J. A., & Drucker, D. J. (2021) · Med · doi:10.1016/j.medj.2021.10.004 · Cited by 50
Self-citationThe Post-amyloid Era in Alzheimer's Disease: Trust Your Gut Feeling
Osorio, C., Kanukuntla, T., Diaz, E., Jafri, N., Cummings, M., & Sfera, A. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00143 · Cited by 49
“It was recently demonstrated that glucagon-like peptide1 (GLP-1) secreted by the gut enteroendocrine (L) cells binds to its receptor, GLP-1R, facilitating immunological tolerance (Yusta et al., 2015).”
BackgroundTargher, G., Mantovani, A., Byrne, C. D., & Tilg, H. (2025) · Gut · doi:10.1136/gutjnl-2024-334023 · Cited by 48
“24 In accordance with a potential role for GLP-1 receptors in gut biology, Glp-1r −/− mice exhibited intestinal dysbiosis and increased sensitivity towards dextran sodium sulfate (DSS) toxicity.”
InfluentialChiou, H.-Y. C., Lin, M.-W., Hsiao, P.-J., Chen, C.-L., Chiao, S., Lin, T.-Y., Chen, Y.-C., Wu, D.-C., & Lin, M.-H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071584 · Cited by 47
“In addition, activation of the GLP-1 receptor on the intestinal intraepithelial lymphocyte suppresses the pro-inflammatory cytokine expression [26].”
BackgroundGLP-1 Receptor: A New Target for Sepsis
Yang, F., Zeng, F., Luo, X., Lei, Y., Li, J., Lu, S., Huang, X., Lan, Y., & Liu, R. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.706908 · Cited by 48
“After activation, GLP-1R can inhibit the release of proinflammatory cytokines IL-2, IL-17A, interferon gamma, and tumor necrosis factor alpha triggered by anti-CD3 and -CD28 antibodies produced by intestinal intraepithelial lymphocytes (Yusta et al., 2015).”
BackgroundDenny, J. E., Powers, J. B., Castro, H. F., Zhang, J., Joshi‐Barve, S., Campagna, S. R., & Schmidt, N. W. (2019) · Scientific Reports · doi:10.1038/s41598-019-40266-6 · Cited by 57
Induced Human Regulatory T Cells Express the Glucagon-like Peptide-1 Receptor
Rode, A. K. O., Buus, T. B., Mraz, V., Al-Jaberi, F. A. H., Lopez, D. V., Ford, S. L., Hennen, S., Eliasen, I. P., Klewe, I. V., Gharehdaghi, L., et al. (2022) · Cells · doi:10.3390/cells11162587 · Cited by 53
“In line with this, two previous studies have demonstrated functional GLP-1R expression in human iNKT cells [9] and in mouse intraepithelial T cells [20], where treatment with GLP-1RA induced increases in the intracellular cAMP concentrations.”
BackgroundResultThe endogenous preproglucagon system is not essential for gut growth homeostasis in mice
Wismann, P., Barkholt, P., Secher, T., Vrang, N., Hansen, H. B., Jeppesen, P. B., Baggio, L. L., Koehler, J. A., Drucker, D. J., Sandoval, D. A., et al. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.04.007 · Cited by 43
“The specific phenotype of these cells is currently unknown but consistent with intraepithelial lymphocytes [59]; however, further studies are needed to confirm this assertion.”
ResultSelf-citationWismann, P., Pedersen, S. L., Hansen, G., Mannerstedt, K., Pedersen, P. J., Jeppesen, P. B., Vrang, N., Fosgerau, K., & Jelsing, J. (2018) · Physiology & Behavior · doi:10.1016/j.physbeh.2018.03.004 · Cited by 43
Huang, J., Yi, H., Zhao, C., Zhang, Y., Zhu, L., Liu, B., He, P., & Zhou, M. (2018) · International Journal of Chronic Obstructive Pulmonary Disease · doi:10.2147/copd.s175145 · Cited by 43
Enteroendocrine Regulation of Nutrient Absorption
McCauley, H. A. (2019) · Journal of Nutrition · doi:10.1093/jn/nxz191 · Cited by 50
Metabolic responses and benefits of glucagon‐like peptide‐1 (GLP‐1) receptor ligands
Tanday, N., Flatt, P. R., & Irwin, N. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15485 · Cited by 41
Shao, S., Zhang, X., Xu, Q., Pan, R., & Chen, Y. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108270 · Cited by 46
Intestinal Immune Imbalance is an Alarm in the Development of IBD
Hu, C. C., Liao, S., Lv, L., Li, C., & Mei, Z. (2023) · Mediators of Inflammation · doi:10.1155/2023/1073984 · Cited by 52
“Glucagon-like peptide 1 receptor (GLP-1R) is widely expressed in various immune cell populations, particularly in intestinal intraepithelial lymphocytes (IELs) [201, 202].”
BackgroundImmune Dysregulation in Obesity
Jiang, Z., Tabuchi, C., Gayer, S. G., & Bapat, S. P. (2025) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-051222-015350 · Cited by 52
Enteroendocrine cells regulate intestinal homeostasis and epithelial function
Nwako, J. G., & McCauley, H. A. (2024) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2024.112339 · Cited by 51
Insights into incretin-based therapies for treatment of diabetic dyslipidemia
Stemmer, K., Finan, B., DiMarchi, R. D., Tschöp, M. H., & Müller, T. D. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.008 · Cited by 43
“In the gastrointestinal tract, protein expression of the GLP-1R was only detected in the HCL-secreting parietal cells and the smooth muscle cells of the stomach, the Brunner's gland of the duodenum, cells of the nervous plexus [132] and intestinal intraepithelial lymphocytes [133], but not on chylomicron forming enter…”
BackgroundRoessler, J., Leistner, D. M., Landmesser, U., & Haghikia, A. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.08.018 · Cited by 40
Arvanitakis, K., Koufakis, T., Popovic, D. S., Maltese, G., Mustafa, O. G., Doumas, M. N., Γιουλεμέ, Ό., Kotsa, K., & Germanidis, G. S. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00506-3 · Cited by 41
Al-Dwairi, A., Alqudah, T., Al-Shboul, O., Alqudah, M., Mustafa, A., & Alfaqih, M. A. (2018) · Journal of Inflammation Research · doi:10.2147/jir.s152835 · Cited by 37
“47 In our study, immunohistochemical staining revealed that GLP-1R is expressed in mouse CSMCs, suggesting that GLP-1 can directly influence CSMC function.”
Gong, B., Li, C., Shi, Z., Wang, F., Dai, R., Chen, G., & Su, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1675552 · Cited by 36
Ngabea, M. A., & Dimeji, I. Y. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152822 · Cited by 35
Genetic disruption of the Gipr in Apoe−/− mice promotes atherosclerosis
Pujadas, G., Baggio, L. L., Kaur, K. D., McLean, B. A., Cao, X., & Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101586 · Cited by 34
Self-citationNassar, M., Nassar, O., Abosheaishaa, H. M., & Misra, A. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02466-4 · Cited by 35
“Notably, [ 20, 21 ].”
Kishida, Y., Okubo, H., Ohno, H., Oki, K., & Yoneda, M. (2017) · Journal of Gastroenterology · doi:10.1007/s00535-017-1331-4 · Cited by 34
Metadata
- Authors
- Yusta, B., Baggio, L. L., Koehler, J., Holland, D., Cao, X., Pinnell, L. J., Johnson-Henry, K. C., Yeung, W., Surette, M. G., Bang, K. W. A., Sherman, P. M., & Drucker, D. J.
- Affiliations
- Mount Sinai Hospital (CA)
- University of Toronto (CA)
- Cell Biology Program, Research Institute, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
- McMaster University (CA)
- Corresponding author
- Drucker, Daniel J.
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2015-03-03
- Volume
- 64
- Issue
- 7
- Pages
- 2537-2549
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W1903699177
- Cited by
- 282
- References
- 56
- Citations by year
- 2026: 25 · 2025: 45 · 2024: 34 · 2023: 20 · 2022: 32 · 2021: 29 · 2020: 20 · 2019: 29 · 2018: 16 · 2017: 18 · 2016: 7 · 2015: 6
- FWCI
- 13.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk Inc
- Canadian Institutes of Health Research (MOP 123391, Novo Nordisk Inc)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Keywords
- GLP-1 receptor agonists, exendin-4, exendin-9-39, intestinal intraepithelial lymphocytes, mucosal immunity, innate immunity, cAMP signaling, gut microbiota, intestinal injury, dextran sodium sulfate, bone marrow transplantation, obesity, cytokine and chemokine expression, epithelial barrier integrity
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Animals, Female, Immunity, Innate, Intestinal Mucosa, Lymphocytes, Male, Mice, Inbred C57BL, Peptides, Venoms, Signal Transduction, Cytokines, Receptors, Glucagon, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.